Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Trial Profile

Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs CUDC 907 (Primary)
  • Indications B cell lymphoma; CNS cancer; Lymphoma; Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 25 May 2017 Acording to a Curis media release, data from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 11 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top